SCHEMBL19982610

SCHEMBL19982610

CCOP(=O)(Cc1ccc(COc2ccccc2CN2CCN(Cc3ccc4nc(-c5cccc(C(F)(F)F)c5)[nH]c4c3)CC2)cc1)OCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
CNR2 P34972 7/20 0.38
FGFR1 P11362 1/20 0.38
FLT1 P17948 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
CNR1 P21554 3/20 0.38
KCNH2 Q12809 1/20 0.37
LMNA P02545 2/20 0.37
GAA P10253 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19982583 0.96 SLC2A1 (0.42) SLC2A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL19982578 0.93 SLC2A1 (0.45) SLC2A1FGFR1FLT1PTGDR2KCNH2
SCHEMBL19970804 0.92 CNR2 (0.40) SLC2A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL19970820 0.90 DRD4 (0.43) SLC2A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL19982561 0.90 SLC2A1 (0.46) SLC2A1HTR2AHTR2CFGFR1FLT1
SCHEMBL19982656 0.88 DRD4 (0.42) SLC2A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL19970889 0.88 SLC2A1 (0.44) SLC2A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL19970747 0.86 DRD4 (0.45) SLC2A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL19982612 0.86 CYP1A2 (0.43) SLC2A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL19970810 0.85 CHEK2 (0.41) SLC2A1FGFR1FLT1KCNH2AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
WO-2018050771-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-22 WO disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS SLC2A1 4852/4885CYP1A2 2067/4885CYP3A4 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.